WEKO3
-
RootNode
アイテム
Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer
http://hdl.handle.net/10458/0002000102
http://hdl.handle.net/10458/000200010289d68413-2158-42a4-9f97-2e5736103128
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文 (370 KB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2023-10-24 | |||||||||
| タイトル | ||||||||||
| タイトル | Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer | |||||||||
| 言語 | en | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| キーワード | caveolin-1 | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| キーワード | caveolin-2 | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| キーワード | CRPC | |||||||||
| キーワード | ||||||||||
| 言語 | en | |||||||||
| 主題Scheme | Other | |||||||||
| キーワード | cell motility | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ | journal article | |||||||||
| 著者 |
上別府, 豊治
× 上別府, 豊治× 山崎, 浩司× 中原, 梢× Nagai, Takahiro
× Terada, Naoki× Tsukino, Hiromasa
× 向井, 尚一郎× 賀本, 敏行 |
|||||||||
| 抄録 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Background: Caveolin (Cav)-1 and Cav-2 are cell membrane proteins, which are structural proteins of caveolae and are reported to be positive regulators of cell survival and metastasis in prostate cancer (PC). In a previous study, we reported that elevated levels of Cav-1 and Cav-2 were significantly associated with PC progression. However, their functions in PC have not yet been clarified. In this study, we examined the function of Cav-1 and Cav-2 in PC cell invasiveness and motility. Materials and methods: We introduced Cav-1- and Cav-2-specific small interfering into PC3 cells to knock-down (KD) both molecules. We also performed cell proliferation assay, wound healing assay, migration assay, and invasion assay using PC3 cells and compared the results between Cav-1-KD, Cav-2-KD, and negative control PC3 cells. In addition, we performed real-time quantitative PCR (RT-qPCR) and RT2 Profiler PCR Array analysis to identify factors influencing migration. Results: We observed no significant difference in the proliferative and invasive activities of Cav-1-KD and Cav-2-KD PC3 cells; however, the cell motility was significantly decreased compared with negative control PC3 cells. RT-qPCR revealed that the expression of vimentin and N-cadherin was downregulated in Cav-1-KD PC3 cells. In addition, PCR array revealed a decreased expression of MGAT5, MMP13, and MYCL in Cav-1-KD PC3 and ETV4, FGFR4, and SRC in Cav-2-KD PC3. Conclusion: Cav-1 and Cav-2 may positively contribute to the upregulation of castration-resistant PC cell migration. Cav-induced regulation of several molecules including vimentin, N-cadherin, MGAT5, MMP13, MYCL, ETV4, FGFR4, and SRC may have an important role in PC3 cell motility. However, further examination will be required. |
|||||||||
| 言語 | en | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | Citation: Kamibeppu T, Yamasaki K, Nakahara K, Nagai T, Terada N, Tsukino H, Mukai S, Kamoto T. Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer. Res Rep Urol. 2018;10:135-144 https://doi.org/10.2147/RRU.S173377 |
|||||||||
| 言語 | en | |||||||||
| 書誌情報 |
en : Research and Reports in Urology 巻 10, p. 135-144, 発行日 2018-10-18 |
|||||||||
| 出版者 | ||||||||||
| 出版者 | Dove Medical Press | |||||||||
| 言語 | en | |||||||||
| DOI | ||||||||||
| 関連タイプ | isVersionOf | |||||||||
| 識別子タイプ | DOI | |||||||||
| 関連識別子 | https://doi.org/10.2147/RRU.S173377 | |||||||||
| 権利 | ||||||||||
| 言語 | en | |||||||||
| 権利情報 | © 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. | |||||||||
| 著者版フラグ | ||||||||||
| 出版タイプ | VoR | |||||||||
Share
Cite as
上別府, 豊治, 山崎, 浩司, 中原, 梢, Nagai, Takahiro, Terada, Naoki, Tsukino, Hiromasa, 向井, 尚一郎, 賀本, 敏行, 2018, Caveolin-1 and -2 regulate cell motility in castration-resistant prostate cancer: Dove Medical Press, 135–144 p.
Loading...
